Payment overview · 2025
General Payments
$135.51
7 reported records · 5 companies
Healthcare provider profile · identity verified
Cary Patrick Sullivan, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · VIAN, OK · NPI 1497701130
Verified facts
What the public records show
CMS Open Payments records show Cary Patrick Sullivan, D.O. received $135.51 in general payments during 2025 across 7 reported records.
Astellas Pharma US Inc accounted for 33.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $45.05 | 33.2% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $32.67 | 24.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.41 | 16.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.32 | 14.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.06 | 11.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $135.51 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $45.05 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $41.73 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $32.67 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 85 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
74 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 485 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 352 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 347 | 57 |
| Lisinopril | Lisinopril | 345 | 73 |
| Omeprazole | Omeprazole | 326 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 227 | 54 |
| Gabapentin | Gabapentin | 212 | 40 |
| Furosemide | Furosemide | 207 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 206 | 42 |
| Potassium Chloride | Potassium Chloride | 190 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 185 | 37 |
| Losartan Potassium | Losartan Potassium | 179 | 55 |
| Tramadol Hcl | Tramadol Hcl | 171 | 35 |
| Trazodone Hcl | Trazodone Hcl | 160 | 36 |
| Metformin Hcl | Metformin Hcl | 159 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 139 | 44 |
| Eliquis | Apixaban | 138 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 35 |
| Carvedilol | Carvedilol | 131 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 28 |
| Sertraline Hcl | Sertraline Hcl | 114 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 106 | 31 |
| Buspirone Hcl | Buspirone Hcl | 96 | 18 |
| Metformin Hcl Er | Metformin Hcl | 96 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 89 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 25 |
| Jardiance | Empagliflozin | 85 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 29 |
| Simvastatin | Simvastatin | 79 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 12 |
| Pregabalin | Pregabalin | 74 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 13 |
| Xarelto | Rivaroxaban | 70 | 11 |
| Ezetimibe | Ezetimibe | 66 | 14 |
| Montelukast Sodium | Montelukast Sodium | 64 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 14 |
| Warfarin Sodium | Warfarin Sodium | 63 | suppressed |
| Meloxicam | Meloxicam | 62 | 20 |
| Prednisone | Prednisone | 61 | 33 |
| Allopurinol | Allopurinol | 59 | 16 |
| Donepezil Hcl | Donepezil Hcl | 59 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 53 |
| Myrbetriq | Mirabegron | 56 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | suppressed |
| Alprazolam | Alprazolam | 53 | suppressed |
| Ozempic | Semaglutide | 49 | 11 |
| Divalproex Sodium | Divalproex Sodium | 48 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | suppressed |
| Nystatin | Nystatin | 46 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Mirtazapine | Mirtazapine | 45 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Sucralfate | Sucralfate | 39 | suppressed |
| Trulicity | Dulaglutide | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | suppressed |
| Glimepiride | Glimepiride | 35 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Novolog | Insulin Aspart | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | 12 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Cephalexin | Cephalexin | 32 | 30 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 28 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 24 |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | 12 |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 24 |
| Celecoxib | Celecoxib | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 20 |
| Olanzapine | Olanzapine | 21 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 17 |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Acetic Acid | Acetic Acid | 15 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $135.51 · 7 records | Astellas Pharma US Inc | JARDIANCE, TRELEGY ELLIPTA, Veozah, YUPELRI | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error